Past performance
Performance overview
About Asston Pharmaceuticals Ltd Asston Pharmaceuticals Limited, established on April 16, 2019, began as a contract manufacturer specializing in pharmaceutical products for export markets. Over time, the company expanded its operations by acquiring Ferron Lifecare Private Limited in April 2024, integrating nutraceutical manufacturing capabilities. The transformation from a private to a public limited company occurred on August 29, 2024, with FDA approval for its Ambarnath production facility granted later that year. The company produces and markets a diverse portfolio of pharmaceutical formulations and nutraceutical products under the "Asston" brand, targeting both domestic and African markets. Its product range includes tablets, capsules, syrups, ointments, gels, lotions, and powdered formulations like sachets and dry syrups. The company's manufacturing facility in Ambernath, Maharashtra, has a production capacity of 8-9 crore tablets per month, with current production averaging 5-6 crore tablets. Additionally, the facility can produce around 37.5 kiloliters of syrup and 30-40 lakh sachets per month, subject to product specifications. The facility meets regulatory standards and is periodically audited by both state and central FDA authorities. Asston Pharmaceuticals operates with a focus on quality and expertise, leveraging the experience of its founders to maintain efficient supply chain management and production standards. Besides in-house manufacturing, the company engages contract manufacturers for producing generic medicines and antibiotics in multiple forms, ensuring flexibility in its production capabilities. In line with its expansion strategy, the company plans to launch an Initial Public Offering (IPO) of 22,41,600 equity shares with a face value of Rs. 10 each. This move reflects Asston Pharmaceuticals' growth ambitions and its positioning as a key player in the pharmaceutical and nutraceutical sectors.
Founded 2019
Headquarters Mumbai